Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
New findings suggest that liposome-mediated delivery of a specific microRNA inhibitor can restore anti-inflammatory macrophage polarization and reduce joint inflammation in mice.
Although inflammatory arthritis induced by immune-checkpoint inhibitors clinically resembles that of rheumatoid arthritis or psoriatic arthritis, research shows that it differs in its associated T cell response.
Nanoparticles consisting of long DNA molecules in association with Ca2+ and PPi4− ions can modulate the pathological osteoporotic microenvironment and promote bone repair.
New research provides insights into the mechanisms underlying the renal protective effects of sodium glucose cotransporter 2 inhibitors in lupus nephritis.
An antibody that targets CD19 on B cells has shown greater inhibitory efficacy than that of anti-CD20 B cell depletion therapy in animal models of autoimmune diseases.
New research indicates that extracellular aminoacyl-tRNA synthetases contribute to the pathogenesis of rheumatoid arthritis by functioning as alarmins, and could be a novel therapeutic target.
Researchers have developed ‘urchin-like’ ceria nanoparticles with inherent antioxidant properties that efficiently carry therapeutic microRNA, enabling gene therapy following intra-articular injection in a mouse model of osteoarthritis.
Platelet activity and the formation of monocyte–platelet aggregates contribute to the production of IL-1β and the development of cardiovascular lesions in Kawasaki disease.
In a phase III trial, the oral Janus kinase inhibitor baricitinib was safe and effective in patients with juvenile idiopathic arthritis who previously had an inadequate response to DMARD therapy.
New findings suggest that interosseous tendon inflammation is already present in individuals with clinically suspect arthralgia and is linked to an increased risk of developing clinical arthritis.
IL-17 signalling regulates both protective and harmful immune responses; therefore, its complete inhibition can have adverse effects. Detailed consideration and fine-tuning of IL-17-inhibition strategies is needed to selectively regulate disease outcomes.
A new report indicates that low back pain remains the leading cause of disability worldwide, and that case numbers are expected to increase substantially in the coming decades.
New findings implicate TAp63 as a potential target of methotrexate in T cells, providing insight in the mechanism of action of this drug, including its suppressive effects on regulatory T cells.
New findings suggest that neutrophil extracellular traps and their components have a functional role as triggers of IL-17-mediated inflammation and associated bone destruction in periodontitis.
Researchers have co-cultured human mesenchymal stromal cells and monocytes to generate bone-like structures that have the potential to facilitate the study of bone remodelling in vitro.
The ACR has developed its first guideline for managing rheumatoid arthritis using integrative interventions, to aid in decision-making regarding such approaches alongside pharmacological treatment.